London
Roots Analysis has announced theaddition of “Endocannabinoid System Targeted Therapeutics Market, 2020-2030” report to its list of offerings.
Overtime, extensive R&D on the potential health benefits of cannabis, haveenabled medical researchers to identify a number of pharmacologically activeingredients that offer clinical benefit, minus the addictive properties of thecrude substance. Currently, several stakeholders in the pharmaceutical industryare actively engaged in the efforts to develop leads based on natural andsynthetic derivatives of cannabinoids.
To order this 250+ page report, whichfeatures 140+ figures and 170+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html
Key MarketInsights
Over 175 drugstargeting the endocannabinoid system are currently under development
Most cannabinoid-baseddrug candidates are being developed to target the CB1 and CB2 receptors. Nearly45% of such drugs are presently being investigated in clinical trials, while 50%are in the preclinical / discovery phase. Majorityof these therapies (60%) are designed for oral administration.
More than60 companies claim to develop endocannabinoid system targeted therapeutics
Post2010, there has been a significant rise in the number of companies working inthis domain; such companies represent 63% of the total number of players. Majorityof the firms engaged in this domain (74%) are based in North America, followedby those headquartered in Asia-Pacific (16%), Europe (8%) and Latin America(2%).
Partnershipactivity has grown at an annualized rate of 35%, between 2017 and 2019
The maximumnumber of partnerships were observed in 2019 within this segment of thepharmaceutical industry. Majority of these agreements were reported to have beeninked for research purposes (20%). In addition, more than 35 merger /acquisition deal were signed between 2016 and 2020; service / facilityexpansion emerged as the most prominent key value drivers for such agreements.
Close to 600grants were awarded for supporting research on endocannabinoid system targetedtherapeutics, since 2016
Almost 45%of the total amount awarded in the form of grants, was under the R01 (insupport of health-related research and development based on the mission ofthe NIH) mechanism. Further, grants (394) worth USD 147 million wereawarded to research projects related to endocannabinoid system.
Atpresent, therapies intended for the treatment of neurological disorders representthe majority share of the overall endocannabinoid system targeted therapeuticsmarket
Most of the therapies targeting neurologicaldisorders are intended for the treatment of epilepsy. In addition to neurologicaldisorders, therapies intended for autoimmune disorders, cancer and geneticdisorders are likely to capture significant market opportunity in the foreseen future.
To request a sample copy / brochure of thisreport, please visit this - https://www.rootsanalysis.com/reports/316/request-sample.html
KeyQuestions Answered
§ Who are the leading industry players in this market?
§ What are the key clinical conditions addressed by endocannabinoidsystem targeted therapeutics?
§ What are the biological receptors targeted by cannabinoid-basedtherapies?
§ What are the factors that are likely to influence the evolutionof this market?
§ What are the initiatives undertaken by start-ups and big pharmaplayers engaged in this domain?
§ What kind of partnership models are commonly adopted bystakeholders in this industry?
§ How is the current and future market opportunity likely to bedistributed across key market segments?
The over USD 5 billion (by 2030) financialopportunity within the endocannabinoid system targeted therapeutics market has been analyzed across thefollowing segments:
§ TargetDisease Indication
- Cancer
- Genetic Disorders
- Neurological Indications
- Others
§ Route of Administration
- Oral
- Inhalation
§ Key Geographies
- North America
- Europe
- Asia-Pacific and the Rest of the World
Thereport features inputs from eminent industry stakeholders, according to whom, endocannabinoidsystem targeted therapeutics are considered as a promising alternative for thetreatment of a diverse array of symptoms associated with a myriad of human diseases.The report includes detailed transcripts of the discussions held with industry experts.
§ OludareOdumosu (Chief Executive Officer, Zelira Therapeutics)
§ AndreaSmall-Howard (Chief Scientific Officer, GB Sciences)
§ SteeveNéron (Chief Operating Officer, Tetra Bio-Pharma)
§ StephenDahmer (Chief Medical Officer, Vireo Health)
§ AnthonyKievid (Director of Business Development, Echo Pharmaceuticals)
§ JANAKANKRISHNARAJAH (Chief Operating Officer and Chief Medical Officer, iX Biopharma)
Theresearch includes detailed profiles of key players (listed below); eachprofile features an overview of the company, itsfinancial information (if available), drug portfolio, recentdevelopments and an informed future outlook.
§ GW Pharmaceuticals
§ Corbus Pharmaceuticals
§ Tilray
§ Tetra Bio-Pharma
§ Botanix Pharmaceuticals
§ Kalytera Therapeutics
§ Therapix Biosciences
§ Echo Pharmaceuticals
§ Avicanna
§ GB Sciences
For additional details, pleasevisit
https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.htmlor email sales@rootsanalysis.com
You may also be interested in thefollowing titles:
1. Neoantigen TargetedTherapies Market, 2019-2030
2. Blood-Brain Barrier(BBB) Market (2nd Edition), 2020-2030: Focus onNon-Invasive Drug Delivery Technology Platforms and Therapeutics
3. Bispecific AntibodyTherapeutics Market (4thEdition), 2019-2030
4. ContinuousManufacturing Market (Small Molecules and Biologics),2020 – 2030
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.Chaudhary@rootsanalysis.com
Facebook Conversations